亞洲的胚胎著床前遺傳基因診斷 (PGD) 市場 (非整倍體篩檢，染色體異常，男女性別選擇，組織相容抗原檢查，單一遺傳基因疾病，X連鎖疾病):產業分析，市場規模、佔有率、成長率、趨勢、預測
Preimplantation Genetic Diagnosis Market (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorder, and X-linked diseases) - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
|出版商||Transparency Market Research||商品編碼||356397|
|出版日期||內容資訊||英文 114 Pages
|亞洲的胚胎著床前遺傳基因診斷 (PGD) 市場 (非整倍體篩檢，染色體異常，男女性別選擇，組織相容抗原檢查，單一遺傳基因疾病，X連鎖疾病):產業分析，市場規模、佔有率、成長率、趨勢、預測 Preimplantation Genetic Diagnosis Market (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorder, and X-linked diseases) - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023|
|出版日期: 2016年03月28日||內容資訊: 英文 114 Pages||
本報告提供亞洲各國的胚胎著床前遺傳基因診斷 (以下PGD) 市場現況與未來展望相關分析，診斷技術概要和相關疾病，市場基本結構，主要的推動及阻礙市場要素，整體市場趨勢預測 (過去3年、今後8年份)，各檢查項目、各終端用戶詳細趨勢，各地區、主要國家的市場結構及趨勢預測，法規環境，主要企業簡介等相關調查。
Title: Preimplantation Genetic Diagnosis Market (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorder, and X-linked diseases; Fertility Clinics, Health Care Facilities, and Academic Institutes and Research Centers) - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.
Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro in order to eliminate a genetic condition in case a high risk of that condition is known. PGD is an evolving technique that provides a practical alternative to prenatal diagnosis and termination of pregnancy for couples who are at substantial risk of transmitting a serious genetic disorder to their offspring. Growing incidence of infertility across the world is the major driver of the PGD market. Preimplantation genetic diagnosis plays an important role in the detection and determination of genetic disorders, sex-linked diseases, and chromosomal abnormalities in the embryo before IVF can be performed. Rising incidence of infertility coupled with growing awareness about IVF and PGD is the major factor driving the PGD market in Asia.
The preimplantation genetic diagnosis (PGD) market in Asia has been segmented based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The market analysis is based on market size and forecast in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) for the period 2015 to 2023, considering 2014 as the base year. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.
The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes Porter's Five Forces Analysis, overview of PGD, Regulatory Policies and Legality Framework for PGD, Heat Map Analysis for key market players, and country-wise number of PGD Centers in Asia. The report provides a detailed industry analysis of the preimplantation genetic diagnosis (PGD) market in Asia with the help of market attractiveness analysis, by geography, for the year 2014.
The market has been analyzed for Asia covering South Eastern Asia, Eastern Asia, Southern Asia, Central Asia, and Western Asia. The market size and forecast of the regional and country-wise markets is provided for the period 2013 to 2023. CAGR (%) for each region is also estimated for the period 2015 to 2023, considering 2014 as the base year. South Eastern Asia includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Rest of SEA. Eastern Asia comprises China, Japan, South Korea, and Rest of Eastern Asia. Southern Asia constitutes India, Sri Lanka, and Rest of Southern Asia. Western Asia includes Israel, Turkey, Jordan, Saudi Arabia, the United Arab Emirates, and Rest of Western Asia. Eastern Asia accounted for the largest share of the PGD market in Asia.
The report also provides recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the PGD market in Asia. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc.(U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.). The market share analysis of key players involved the study of company products or services portfolio, post sales services and maintenance, sales revenue, and its geographical presence.